Do weight loss injections cause muscle loss?

Does any weight loss come from muscle, not just fat?

Yes, and this is true of weight loss by any method, not only injections. When you eat less than your body burns, it draws on stored energy from both adipose tissue and, to a lesser extent, lean tissue including muscle. What distinguishes GLP-1 and dual-agonist medicines is that their mechanism operates through appetite and satiety signalling rather than directly targeting fat or muscle cells, so the composition of what you lose depends largely on what you do alongside treatment.

In the SURMOUNT-1 trial of tirzepatide, published in the New England Journal of Medicine, participants lost an average of around 20–21% of body weight at the highest dose over 72 weeks. Body-composition sub-studies showed the majority of that loss was fat mass. A similar pattern appeared in semaglutide trials. That said, lean mass did decrease in absolute terms, which is why the conversation about what you eat and how you move during treatment matters so much.

The proportion of weight lost as muscle tends to be higher when protein intake is low, when resistance exercise is absent, and when weight loss is very rapid. A prescriber reviewing your treatment's effect on muscle mass will consider all three. Slower titration and modest calorie reduction, rather than aggressive restriction on top of the medicine's appetite suppression, generally produce a healthier body-composition outcome.

What can you actually do to protect your muscle during treatment?

Two things have consistent support: adequate protein and resistance training. NHS guidance for people on weight-management medicines recommends maintaining protein intake even as overall calories fall, a practical challenge given that these medicines significantly reduce appetite. Spreading protein across meals rather than concentrating it in one sitting helps absorption.

Resistance exercise (not necessarily gym-based; bodyweight work, resistance bands or loaded walking all count) signals to the body that lean tissue is needed and worth preserving. Some people find this easier on GLP-1 treatment because they have more energy as their weight falls; others find nausea in the early weeks makes structured activity harder. That usually settles as the body adjusts to the starting dose.

NHS England's guidance for clinicians overseeing weight management injections explicitly emphasises the importance of physical activity and dietary support alongside medication, for exactly this reason. Treatment is meant to be a tool that enables change, not a replacement for the behaviours that make that change stick.

If you're curious how the different injection options compare in terms of how they work and what the evidence shows, that's worth reading before you decide.

Is muscle loss a reason to avoid these medicines?

For most people who meet the clinical criteria, the risks of remaining at a higher body weight (cardiovascular disease, type 2 diabetes, joint deterioration, sleep apnoea) outweigh a modest and manageable reduction in lean mass. That is the clinical calculation NICE made when recommending tirzepatide in TA1026 and semaglutide in TA875, both of which set eligibility thresholds based on weight-related health conditions rather than cosmetic goals.

The question isn't really whether any muscle loss occurs, some degree is almost inevitable with meaningful weight reduction. The question is whether it's clinically significant and what can mitigate it. For the majority of people on a structured programme with adequate protein and some resistance activity, lean mass loss is modest relative to fat loss and does not outweigh the metabolic benefits.

There are situations where the concern carries more weight: older adults, people with existing sarcopenia (age-related muscle loss), and those recovering from illness or surgery. A prescriber considers these factors individually, and our page covering how weight loss injections interact with muscle mass goes into this in useful detail if it is a particular concern for you. The broader context of injections and muscle loss is worth reading if this is a particular concern for you.

These medicines are prescription-only for good reason: tirzepatide (Mounjaro) carries a Black Triangle (▼) designation, meaning MHRA keeps it under enhanced monitoring. That is not a reason for alarm, it is the normal status for recently licensed medicines and means any emerging signals get picked up quickly. You can report side effects, including anything that feels like unusual muscle weakness or changes in physical capacity, at the MHRA's Yellow Card scheme.

How does this affect the consultation process?

A prescriber looking at your suitability for treatment will ask about your activity level, diet, and any conditions relevant to muscle health. That is not bureaucracy, it is the information needed to advise you on how to get the best outcome from treatment, not just whether you qualify for it.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber on the day it's submitted. Not a screening algorithm, not an automated filter. A clinician reads it. Once approved, your treatment is dispatched the same day if received before noon, arriving via DPD the next working day in plain, unbranded packaging, the pen itself neatly packed, ready to go into the fridge door. Aftercare is available seven days a week, which is exactly when questions about things like protein intake or exercise on treatment tend to come up.

If you'd like to explore what treatment might involve for you specifically, our free consultation page is where to start. You can also read about what the evidence says on injections and muscle loss in more detail, or visit our weight loss overview for context on how the different treatments work.